Influence of standardized extract of Epilobium angustifolium on estrogen receptor α and β expression in in vivo model;Wpływ standaryzowanego wyciągu z Epilobium angustifolium na ekspresję mRNA receptorów estrogenowych α i β w modelu in vivo

Ginekologia Polska

Volumn 81, Issue 8, 2010, Pages 600-605

  Radosław, Kujawski ^a   M, Mrozikiewicz Przemysław ^a,b   Anna, Bogacz ^a,b   Joanna, Cichocka ^a   Ł, Mikołajczak Przemysław ^a,b   Bogusław, Czerny ^a,c   Teresa, Bobkiewicz Kozłowska ^b   Edmund, Grześkowiak ^b  

^a INSTITUTE OF NATURAL FIBRES AND MEDICINAL PLANTS   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Epilobium angustifolium; Estrogen receptor and ; Estrogens; Phytotherapeutics; Selective estrogen receptor modulators (SERM)

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; PLANT EXTRACT;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; EPILOBIUM; IN VITRO STUDY; MALE; METABOLISM; PROSTATE; RANDOMIZATION; RAT; WISTAR RAT;

ANIMALS; EPILOBIUM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MALE; PLANT EXTRACTS; PROSTATE; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER;

EID: 77958578599     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Simpson E, Rubin G, Clyne C, [et al.]. Local estrogen biosynthesis in males and females. Endocr Relat Cancer. 1999, 6, 131-137.
2. Frye C. Steroids, reproductive endocrine function, and affect. A review. Minerva Ginecol. 2009, 61, 541-562.
3. Kula K, Słowikowska-Hilczer J, Walczak-Je{ogonek}drzejowska R, [i wsp.]. Znaczenie fizjologiczne estrogenów u me{ogonek}żczyzn-przełom w endokrynologii. IV Konferencja Sekcji Endokrynologii Molekularnej PTE, Poznań, 2-3.10.2004.
4. Prins G, Korach K. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008, 73, 233-244.
5. Drummond A, Fuller P. The importance of ERbeta signalling in the ovary. J Endocrinol. 2010, 205, 15-23.
6. Waters K, Safe S, Gaido W. Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. Toxicol Sci. 2001, 63, 47-56.
7. Gustafsson J. Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol. 1999, 163, 379-383.
8. Morani A, Warner M, Gustafsson J. Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med. 2008, 264, 128-142.
9. Bord S, Horner A, Beavan S, [et al.]. Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab. 2001, 86, 2309-2314.
10. McGuire W. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978, 5, 428-433.
11. Iwao K, Miyoshi Y, Egawa Ch, et al. Quantitative analysis of estrogen receptor-alpha and-beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction. Cancer. 2000; 89, 1732-1738.
12. Mann S, Laucirica R, Carlson N, [et al.]. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001, 32, 113-118.
13. Jarvinen T, Pelto-Huikko M, Holli K, [et al.]. Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade and proliferation rate in breast cancer. Am J Path. 2000, 156, 29-35.
14. Paruthiyil S, Parmar H, Kerekatte V, [et al.]. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004, 64, 42342-8.
15. Lapidus R, Nass S, Davidson N. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia. 1998, 3, 85-94.
16. Fitzpatrick J, Schulman C, Zlotta A, [et al.]. Prostate cancer: a serious disease suitable for prevention, BJU Int. 2009, 103, 864-870.
17. Untergasser R, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissueremodeling. Exp Gerontol. 2005, 40, 121-128.
18. Prins G, Marmer M, Woodham C, [et al.]. Estrogen receptor-β messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats. Endocrinology. 1998, 139, 874-883.
19. Janakiram N, Steele V, Rao C. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethaneinduced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa). 2009, 2, 52-59.
20. Dhingra K. Antiestrogens-tamoxifen, SERMs and beyond. Invest New Drugs. 1999, 17, 285-311.
21. Gallagher J. Advances in bone biology and new treatments for bone loss. Maturitas. 2008, 20, 65-69.
22. Tkaczyk M, Kalita K. Estrogen receptor beta--structure, regulation and function. Postepy Biochem., 2001, 47, 72-79. Polish.
23. Wright J, Stouffer R, Rodland K. Hight-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells. J. Clin Endocrinol Metab. 2001, 90, 3688-3695.
24. Nattinger A. In the clinic. Breast cancer screening and prevention. Ann Intern Med. 2010, 152, ITC41.
25. Baumann C, Castiglione-Gertsch M. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva Ginecol. 2009, 61, 517-539.
26. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002, 137, 805-813.
27. Stokłosa-Kwarcińska H, Skrzypulec V, Rozmus-Warcholińska W. Czy fitoestrogeny zasta{ogonek}pia{ogonek} hormonalna{ogonek} terapie{ogonek} zaste{ogonek}pcza{ogonek}? Gin Prakt. 2003, 11, 39-44.
28. Verleye M, Akwa Y, Liere P, [et al.]. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav. 2005, 82, 712-720.
29. Kosowicz J, Miskowiak B, Konwerska A, [et al.]. Pneumadin in the rat ventral prostate and its hormonal regulation. Horm Metab Res. 2004, 36, 78-81.
30. Vitalone A, Bordi F, Baldazzi C, [et al.]. Anti-proliferative effect on a prostatic epithelial cell line (PZ-HPV-7) by Epilobium angustifolium L. Farmaco. 2001, 56, 483-489.
31. Vitalone A, Guizzetti M, Costa L, [et al.]. Extracts of various species of Epilobium inhibit proliferation of human prostate cells. J Pharm Pharmacol. 2003, 55, 683-690.
32. Ducrey B, Marston A, Göhring S, [et al.]. Inhibition of 5 alpha-reductase and aromatase by the ellagitannins oenothein A and oenothein B from Epilobium species. Planta Med. 1997, 63, 111-114.
33. Lesuisse D, Berjonneau J, Ciot C, [et al.]. Determination of oenothein B as the active 5-alphareductase-inhibiting principle of the folk medicine Epilobium parviflorum. J Nat Prod. 1996, 59, 490-492.
34. Vitalone A, McColl J, Thome D, [et al.]. Characterization of the effect of Epilobium extracts on human cell proliferation. Pharmacology. 2003, 69, 79-87.
35. Steenkamp V. Phytomedicines for the prostate. Fitoterapia. 2003, 74, 545-552.
36. Kiss A, Kowalski J, Melzig M. Induction of neutral endopeptidase activity in PC-3 cells by an aqueous extract of Epilobium angustifolium L. and oenothein B. Phytomedicine. 2006, 13, 284-289.
37. Hevesi B, Houghton P, Habtemariam S, [et al.]. Antioxidant and antiinflammatory effect of Epilobium parviflorum Schreb. Phytother Res. 2009, 23, 719-724.
38. Hevesi B, Blazics B, Kéry A. Polyphenol composition and antioxidant capacity of Epilobium species. J Pharm Biomed Anal. 2009, 49, 26-31.
39. Brewster M, Anderson W, Pop E. Effect of sustained estradiol release in the intact male rat: correlation of estradiol serum levels with actions on body weight, serum testosterone, and peripheral androgen-dependent tissues. Physiol Behav. 1997, 61, 225-229.
40. Lane K, Ricci M, Ho S. Effect of combined testosterone and estradiol-17 beta treatment on the metabolism of E2 in the prostate and liver of noble rats. Prostate. 1997, 30, 256-262.